Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Down – Time to Sell?

Posted by Brenda Bartman on Nov 13th, 2026

Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) shares gapped down prior to trading on Wednesday. The stock had previously closed at $4.08, but opened at $3.81. Anbio Biotechnology shares last traded at $3.97, with a volume of 1,856 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Hold rating. According to data from MarketBeat.com, Anbio Biotechnology has a consensus rating of “Hold”.

View Our Latest Report on Anbio Biotechnology

Anbio Biotechnology Trading Down 6.2%

The business’s 50 day simple moving average is $4.81 and its 200 day simple moving average is $16.14.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Anbio Biotechnology stock. State Street Corp bought a new position in Anbio Biotechnology (NASDAQ:NNNN – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 25,608 shares of the company’s stock, valued at approximately $161,000.

Anbio Biotechnology Company Profile

(Get Free Report)

Anbio Biotechnology is a medical technology company focused on in vitro diagnostic products used to detect and monitor health conditions. Its offerings include diagnostic testing systems and related products designed for clinical and point-of-care settings. The company’s product portfolio includes testing equipment and diagnostic reagents, supporting the analysis of patient samples. These tools are intended to help healthcare providers obtain test results outside or alongside conventional laboratory workflows.